Smith & Nephew logo

SNN - Smith & Nephew Share Price

$42.98 0.6  1.3%

Last Trade - 9:10pm

Large Cap
Market Cap £13.30bn
Enterprise Value £14.67bn
Revenue £3.25bn
Position in Universe 607th / 6851
Unlock SNN Revenue
Relative Strength (%)
1m +11.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.00%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
4,634 4,669 4,765 4,904 5,138 4,560 5,310 5,645 -0.3%
+22.5 -25.3 +28.8 +2.0 -2.8 -23.7 +28.5 +20.6
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, Smith &Nephew plc revenues decreased 11% to $4.56B. Net incomedecreased 25% to $448M. Revenues reflect Orthopaedicssegment decrease of 14% to $1.92B, Sports Medicine & ENTsegment decrease of 13% to $1.33B, Advanced WoundManagement segment decrease of 5% to $1.31B, United Statesof America segment decrease of 8% to $2.34B, Emerging&internatiuonal market segment decrease of 19% to $771M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


SNN Revenue Unlock SNN Revenue

Net Income

SNN Net Income Unlock SNN Revenue

Normalised EPS

SNN Normalised EPS Unlock SNN Revenue

PE Ratio Range

SNN PE Ratio Range Unlock SNN Revenue

Dividend Yield Range

SNN Dividend Yield Range Unlock SNN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SNN EPS Forecasts Unlock SNN Revenue
Profile Summary

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated February 17, 1937
Public Since August 13, 1951
No. of Shareholders: 14,511
No. of Employees: 17,914
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange New York Stock Exchange (Dual Listing)
Shares in Issue 439,519,975
Free Float (0.0%)
Eligible for
SNN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SNN
Upcoming Events for SNN
Thursday 29th July, 2021
Half Year 2021 Smith & Nephew PLC Earnings Release
Thursday 4th November, 2021
Q3 2021 Smith & Nephew PLC Trading Statement Release
Frequently Asked Questions for Smith & Nephew
What is the Smith & Nephew share price?

As of 9:10pm, shares in Smith & Nephew are trading at $42.98, giving the company a market capitalisation of £13.30bn. This share price information is delayed by 15 minutes.

How has the Smith & Nephew share price performed this year?

Shares in Smith & Nephew are currently trading at $42.98 and the price has moved by 11.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Smith & Nephew price has moved by -22.06% over the past year.

What are the analyst and broker recommendations for Smith & Nephew?

Of the analysts with advisory recommendations for Smith & Nephew, there are there are currently 4 "buy" , 7 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Smith & Nephew is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Smith & Nephew next release its financial results?

Smith & Nephew is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Smith & Nephew dividend yield?

The Smith & Nephew dividend yield is 1.07% based on the trailing twelve month period.

Does Smith & Nephew pay a dividend?

Last year, Smith & Nephew paid a total dividend of 0.45, and it currently has a trailing dividend yield of 1.07%. Looking ahead, Smith & Nephew has not announced an ex-dividend date yet.

When does Smith & Nephew next pay dividends?

Smith & Nephew has yet to annouce their ex-dividend date. The historic dividend yield on Smith & Nephew shares is currently 1.07%.

How do I buy Smith & Nephew shares?

To buy shares in Smith & Nephew you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Smith & Nephew?

Shares in Smith & Nephew are currently trading at $42.98, giving the company a market capitalisation of £13.30bn.

Where are Smith & Nephew shares listed? Where are Smith & Nephew shares listed?

Here are the trading details for Smith & Nephew:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: SNN
What kind of share is Smith & Nephew?

Based on an overall assessment of its quality, value and momentum, Smith & Nephew is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Smith & Nephew share price forecast 2021?

Shares in Smith & Nephew are currently priced at $42.98. At that level they are trading at 9.97% discount to the analyst consensus target price of 0.00.

Analysts covering Smith & Nephew currently have a consensus Earnings Per Share (EPS) forecast of 1.712 for the next financial year.

How can I tell whether the Smith & Nephew share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Smith & Nephew. Over the past six months, the relative strength of its shares against the market has been -6.39%. At the current price of $42.98, shares in Smith & Nephew are trading at 4.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Smith & Nephew PE Ratio?

The Smith & Nephew PE ratio based on its reported earnings over the past 12 months is 31.84. The shares are currently trading at $42.98.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Smith & Nephew?

Smith & Nephew's management team is headed by:

Roberto Quarta - NEC
Erik Engstrom - NID
Robin Freestone - NID
Elga Lohler - CHO
Brad Cannon - CEX
Vasant Padmanabhan - CEX
Roland Diggelmann - CEO
Simon Fraser - CEX
Mark Gladwell - CEX
Skip Kiil - CEX
Myra Eskes - CEX
Anne-Francoise Nesmes - CFO
Katarzyna Mazur-Hofsaess - NID
John Ma - NID
Peter Coenen - CEX
Who are the major shareholders of Smith & Nephew?

Here are the top five shareholders of Smith & Nephew based on the size of their shareholding:

WCM Investment Management Investment Advisor
Percentage owned: 1.67% (7.34m shares)
Nuance Investments, LLC Investment Advisor
Percentage owned: 1.66% (7.28m shares)
Fiduciary Management, Inc. Investment Advisor
Percentage owned: 1.56% (6.86m shares)
Nuance Mid Cap Value Fund Mutual Fund
Percentage owned: 0.8% (3.52m shares)
Northern Trust Global Investments Investment Advisor
Percentage owned: 0.44% (1.91m shares)
Similar to SNN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.